Orasure Technologies Inc (NASDAQ:OSUR)
| Market Cap | 256.46M+15.0% |
| Revenue (ttm) | 112.41M-18.9% |
| Net Income | -49.13M+3.7% |
| EPS | -0.69-2.9% |
| Shares Out | 68.85M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | Jan 8, 1998 |
| Volume | 65,754.881 |
| Open | 3.70 |
| Previous Close | 3.73 |
| Day's Range | 3.69 - 3.75 |
| 52-Week Range | 2.08 - 4.58 |
| Beta | 1.02 |
| Analysts | Hold |
| Price Target | 4.00(+7.38%) |
| Earnings Date | Nov 4, 2026 |
Insiders here have filed 2 Form 4s in the last 90 days, but all of them are share awards, grants or other non-market transactions. Those are compensation, not a decision to buy, so they are not scored.
About OSUR
OraSure Technologies, Inc. and its affiliates are a global leader in the development, production, and commercialization of advanced oral fluid diagnostic solutions and specialized specimen collection tools, serving markets across the United States, Europe, and other international regions. The company operates through two primary divisions: Diagnostics and Molecular Solutions. Its diverse Diagnostics portfolio features a range of crucial offerings, such as the InteliSwab rapid tests for COVID-19 (including professional and prescription versions). It also provides several OraQuick rapid tests, encompassing solutions for HIV (Rapid, In-Home, and Self-Test versions), Hepatitis C (HCV rapid antibody), and Ebola (rapid antigen). Further diagnostic tools include the OraSure oral fluid collection device, utilized for HIV-1 antibody screening and confirmation; the Intercept drug testing systems; various immunoassay tests and reagents; and the Q.E.D. saliva alcohol test. Within its Molecular Solutions segment, OraSure offers an array of genomic products, notably under the Oragene and ORAcollect brand names, alongside specialized microbiome collection solutions and comprehensive GenoFIND genomics laboratory services. The company also supplies collection devices like ORAcollect, RNA, OMNIgene, and RAL, specifically designed for COVID-19 molecular testing. Another key offering is the Colli-Pee device, engineered for the precise volumetric collection of first-void urine. Furthermore, OraSure produces and distributes advanced kits for the collection, stabilization, transportation, and storage of genetic material samples, critical for molecular testing in diverse fields such as academic research, commercial applications (including ancestry, disease risk management, lifestyle analysis), and animal testing. Complementing these, it also provides various other diagnostic tools, including immunoassays and in vitro diagnostic tests. OraSure's sophisticated products and services are distributed to a wide array of clients, including clinical laboratories, hospitals, clinics, various community and public health organizations, wholesale distributors, governmental bodies, medical practices, and a broad spectrum of commercial and industrial entities. Established in 2000, OraSure Technologies, Inc. maintains its corporate headquarters in Bethlehem, Pennsylvania.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
$OSUR stock is featured in our Insider Trades datasets.
→ All Stock ListsRecently reported changes in OSUR holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by OSUR's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
OSUR Estimated quarterly lobbying spending
Source: U.S. Senate LDA
OSUR Revenue by Segment or Geography
| Segment | Revenue | % of All |
|---|---|---|
| Products and services | $29.72M | 97.01% |
| Other | $915.00K | 2.99% |
| COVID-19 | $1.00K | 0.00% |
As of: Q2 2026 (Jun 30, 2026) · Source: SEC EDGAR (10-Q)
U.S. Patents
New OSUR patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to OSUR from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in OSUR
| ETF | Est. Holding Size |
|---|---|
| VTIVanguard Morningstar Total Stock Market ETF | $7.71M |
| IWMiShares Russell 2000 ETF | $6.22M |
| VXFVanguard Extended Market ETF | $2.89M |
| DFSVU.S. Small Cap Value Portfolio ETF Class Shares | $2.44M |
| DFASDimensional - US Small Cap ETF | $2.02M |
| VTWOVanguard Russell 2000 ETF | $1.35M |
Estimated from each fund’s disclosed top holdings × AUM
OSUR Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from OSUR’s recent data — informational, not investment advice
